Reviews - 4mi5 mentioned but not cited (6)
- Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges. Chen Y, Liu X, Li Y, Quan C, Zheng L, Huang K. Comput Struct Biotechnol J 16 211-223 (2018)
- Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease. Cai Q, Gan C, Tang C, Wu H, Gao J. Front Pharmacol 12 784591 (2021)
- Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets. Liu R, Wu J, Guo H, Yao W, Li S, Lu Y, Jia Y, Liang X, Tang J, Zhang H. MedComm (2020) 4 e292 (2023)
- Allosteric regulation of histone lysine methyltransferases: from context-specific regulation to selective drugs. Davidovich C, Zhang Q. Biochem Soc Trans 49 591-607 (2021)
- Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2. Singh K, Gollapudi S, Mittal S, Small C, Kumar J, Ohgami RS. Diagnostics (Basel) 11 600 (2021)
- Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders. Tomassi S, Romanelli A, Zwergel C, Valente S, Mai A. J Med Chem 64 11774-11797 (2021)
Articles - 4mi5 mentioned but not cited (11)
- Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. Justin N, Zhang Y, Tarricone C, Martin SR, Chen S, Underwood E, De Marco V, Haire LF, Walker PA, Reinberg D, Wilson JR, Gamblin SJ. Nat Commun 7 11316 (2016)
- Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance. Brooun A, Gajiwala KS, Deng YL, Liu W, Bolaños B, Bingham P, He YA, Diehl W, Grable N, Kung PP, Sutton S, Maegley KA, Yu X, Stewart AE. Nat Commun 7 11384 (2016)
- Structural insights into conformational stability of both wild-type and mutant EZH2 receptor. Aier I, Varadwaj PK, Raj U. Sci Rep 6 34984 (2016)
- Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. Bisserier M, Wajapeyee N. Blood 131 2125-2137 (2018)
- Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain. Antonysamy S, Condon B, Druzina Z, Bonanno JB, Gheyi T, Zhang F, MacEwan I, Zhang A, Ashok S, Rodgers L, Russell M, Gately Luz J. PLoS One 8 e84147 (2013)
- Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas. Calebiro D, Grassi ES, Eszlinger M, Ronchi CL, Godbole A, Bathon K, Guizzardi F, de Filippis T, Krohn K, Jaeschke H, Schwarzmayr T, Bircan R, Gozu HI, Sancak S, Niedziela M, Strom TM, Fassnacht M, Persani L, Paschke R. J Clin Invest 126 3383-3388 (2016)
- Ezh1 arises from Ezh2 gene duplication but its function is not required for zebrafish development. Völkel P, Bary A, Raby L, Chapart A, Dupret B, Le Bourhis X, Angrand PO. Sci Rep 9 4319 (2019)
- Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoni. Anderson L, Gomes MR, daSilva LF, Pereira ADSA, Mourão MM, Romier C, Pierce R, Verjovski-Almeida S. PLoS Negl Trop Dis 11 e0005539 (2017)
- 5-Methoxyquinoline Derivatives as a New Class of EZH2 Inhibitors. Xiang P, Jie H, Zhou Y, Yang B, Wang HJ, Hu J, Hu J, Yang SY, Zhao YL. Molecules 20 7620-7636 (2015)
- A Comparative Study of Systems Pharmacology and Gene Chip Technology for Predicting Targets of a Traditional Chinese Medicine Formula in Primary Liver Cancer Treatment. Li S, Sun Y, Sun Y. Front Pharmacol 13 768862 (2022)
- Proteomics Reveals an Increase in the Abundance of Glycolytic and Ethanolic Fermentation Enzymes in Developing Sugarcane Culms During Sucrose Accumulation. Boaretto LF, Labate MTV, Franceschini LM, Cataldi TR, Budzinski IGF, de Moraes FE, Labate CA. Front Plant Sci 12 716964 (2021)
Reviews citing this publication (20)
- PRC2 is high maintenance. Yu JR, Lee CH, Oksuz O, Stafford JM, Reinberg D. Genes Dev 33 903-935 (2019)
- Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer. Laugesen A, Højfeldt JW, Helin K. Cold Spring Harb Perspect Med 6 a026575 (2016)
- The molecular principles of gene regulation by Polycomb repressive complexes. Blackledge NP, Klose RJ. Nat Rev Mol Cell Biol 22 815-833 (2021)
- Molecular architecture of polycomb repressive complexes. Chittock EC, Latwiel S, Miller TC, Müller CW. Biochem Soc Trans 45 193-205 (2017)
- Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Brien GL, Valerio DG, Armstrong SA. Cancer Cell 29 464-476 (2016)
- Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Xu B, Konze KD, Jin J, Wang GG. Exp Hematol 43 698-712 (2015)
- Roles of H3K36-specific histone methyltransferases in transcription: antagonizing silencing and safeguarding transcription fidelity. Huang C, Zhu B. Biophys Rep 4 170-177 (2018)
- Engaging chromatin: PRC2 structure meets function. Chammas P, Mocavini I, Di Croce L. Br J Cancer 122 315-328 (2020)
- Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 'Readout', and Phase Separation-Based Compaction. Guo Y, Zhao S, Wang GG. Trends Genet 37 547-565 (2021)
- Structure, mechanism, and regulation of polycomb-repressive complex 2. Moritz LE, Trievel RC. J Biol Chem 293 13805-13814 (2018)
- Polycomb repressive 2 complex-Molecular mechanisms of function. Kouznetsova VL, Tchekanov A, Li X, Yan X, Tsigelny IF. Protein Sci 28 1387-1399 (2019)
- EZH2: an emerging role in melanoma biology and strategies for targeted therapy. Tiffen J, Gallagher SJ, Hersey P. Pigment Cell Melanoma Res 28 21-30 (2015)
- Histone lysine methyltransferases as anti-cancer targets for drug discovery. Liu Q, Wang MW. Acta Pharmacol Sin 37 1273-1280 (2016)
- PRC2, Chromatin Regulation, and Human Disease: Insights From Molecular Structure and Function. Liu X, Liu X. Front Oncol 12 894585 (2022)
- A Structural Perspective on Gene Repression by Polycomb Repressive Complex 2. Liu X. Subcell Biochem 96 519-562 (2021)
- EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies. Wang B, Liu Y, Liao Z, Wu H, Zhang B, Zhang L. Exp Hematol Oncol 12 52 (2023)
- Epigenetic regulation of embryonic ectoderm development in stem cell differentiation and transformation during ontogenesis. Huang L, Li F, Ye L, Yu F, Wang C. Cell Prolif 56 e13413 (2023)
- Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer. Gao M, Li Y, Cao P, Liu H, Chen J, Kang S. Front Oncol 13 1216289 (2023)
- Rare diseases of epigenetic origin: Challenges and opportunities. Fu MP, Merrill SM, Sharma M, Gibson WT, Turvey SE, Kobor MS. Front Genet 14 1113086 (2023)
- Tumor-suppressive functions of protein lysine methyltransferases. Aziz N, Hong YH, Kim HG, Kim JH, Cho JY. Exp Mol Med 55 2475-2497 (2023)
Articles citing this publication (26)
- Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2. Jiao L, Liu X. Science 350 aac4383 (2015)
- Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, Allison DF, Cai L, Rockowitz S, Liu S, Liu Y, Li F, Vedadi M, Frye SV, Garcia BA, Zheng D, Jin J, Wang GG. Blood 125 346-357 (2015)
- Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Gibaja V, Shen F, Harari J, Korn J, Ruddy D, Saenz-Vash V, Zhai H, Rejtar T, Paris CG, Yu Z, Lira M, King D, Qi W, Keen N, Hassan AQ, Chan HM. Oncogene 35 558-566 (2016)
- Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription. Salerno D, Chiodo L, Alfano V, Floriot O, Cottone G, Paturel A, Pallocca M, Plissonnier ML, Jeddari S, Belloni L, Zeisel M, Levrero M, Guerrieri F. Gut 69 2016-2024 (2020)
- Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Tiffen JC, Gunatilake D, Gallagher SJ, Gowrishankar K, Heinemann A, Cullinane C, Dutton-Regester K, Pupo GM, Strbenac D, Yang JY, Madore J, Mann GJ, Hayward NK, McArthur GA, Filipp FV, Hersey P. Oncotarget 6 27023-27036 (2015)
- Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Baker T, Nerle S, Pritchard J, Zhao B, Rivera VM, Garner A, Gonzalvez F. Oncotarget 6 32646-32655 (2015)
- Mrg15 stimulates Ash1 H3K36 methyltransferase activity and facilitates Ash1 Trithorax group protein function in Drosophila. Huang C, Yang F, Zhang Z, Zhang J, Cai G, Li L, Zheng Y, Chen S, Xi R, Zhu B. Nat Commun 8 1649 (2017)
- Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma. Tiffen J, Wilson S, Gallagher SJ, Hersey P, Filipp FV. Neoplasia 18 121-132 (2016)
- The Human Mixed Lineage Leukemia 5 (MLL5), a Sequentially and Structurally Divergent SET Domain-Containing Protein with No Intrinsic Catalytic Activity. Mas-Y-Mas S, Barbon M, Teyssier C, Déméné H, Carvalho JE, Bird LE, Lebedev A, Fattori J, Schubert M, Dumas C, Bourguet W, le Maire A. PLoS One 11 e0165139 (2016)
- Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors. Yang X, Li F, Konze KD, Meslamani J, Ma A, Brown PJ, Zhou MM, Arrowsmith CH, Kaniskan HÜ, Vedadi M, Jin J. J Med Chem 59 7617-7633 (2016)
- An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors. Bratkowski M, Yang X, Liu X. Sci Rep 8 9092 (2018)
- Recent Structural Insights into Polycomb Repressive Complex 2 Regulation and Substrate Binding. Kasinath V, Poepsel S, Nogales E. Biochemistry 58 346-354 (2019)
- Histone H3 Serine 28 Is Essential for Efficient Polycomb-Mediated Gene Repression in Drosophila. Yung PY, Stuetzer A, Fischle W, Martinez AM, Cavalli G. Cell Rep 11 1437-1445 (2015)
- Cooperative DNA looping by PRC2 complexes. Lin X, Leicher R, Liu S, Zhang B. Nucleic Acids Res 49 6238-6248 (2021)
- Polycomb repressive complex 2 in an autoinhibited state. Bratkowski M, Yang X, Liu X. J Biol Chem 292 13323-13332 (2017)
- Discovery of selective activators of PRC2 mutant EED-I363M. Suh JL, Barnash KD, Abramyan TM, Li F, The J, Engelberg IA, Vedadi M, Brown PJ, Kireev DB, Arrowsmith CH, James LI, Frye SV. Sci Rep 9 6524 (2019)
- Full methylation of H3K27 by PRC2 is dispensable for initial embryoid body formation but required to maintain differentiated cell identity. Miller SA, Damle M, Kim J, Kingston RE. Development 148 dev196329 (2021)
- SAH derived potent and selective EZH2 inhibitors. Kung PP, Huang B, Zehnder L, Tatlock J, Bingham P, Krivacic C, Gajiwala K, Diehl W, Yu X, Maegley KA. Bioorg Med Chem Lett 25 1532-1537 (2015)
- Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments. Mieczkowska IK, Pantelaiou-Prokaki G, Prokakis E, Schmidt GE, Müller-Kirschbaum LC, Werner M, Sen M, Velychko T, Jannasch K, Dullin C, Napp J, Pantel K, Wikman H, Wiese M, Kramm CM, Alves F, Wegwitz F. Cell Death Dis 12 1118 (2021)
- Structural analysis of an active fungal PRC2. Jiao L, Liu X. Nucleus 7 284-291 (2016)
- Co-occurrence of a maternally inherited DNMT3A duplication and a paternally inherited pathogenic variant in EZH2 in a child with growth retardation and severe short stature: atypical Weaver syndrome or evidence of a DNMT3A dosage effect? Polonis K, Blackburn PR, Urrutia RA, Lomberk GA, Kruisselbrink T, Cousin MA, Boczek NJ, Hoppman NL, Babovic-Vuksanovic D, Klee EW, Pichurin PN. Cold Spring Harb Mol Case Stud 4 a002899 (2018)
- Combined HAT/EZH2 modulation leads to cancer-selective cell death. Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-Megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L. Oncotarget 9 25630-25646 (2018)
- Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Chase A, Score J, Lin F, Bryant C, Waghorn K, Yapp S, Carreno-Tarragona G, Aranaz P, Villasante A, Ernst T, Cross NCP. Leukemia 34 3206-3214 (2020)
- Structural insights into binding of small molecule inhibitors to Enhancer of Zeste Homolog 2. Kalinić M, Zloh M, Erić S. J Comput Aided Mol Des 28 1109-1128 (2014)
- The transcriptional elongation factor CTR9 demarcates PRC2-mediated H3K27me3 domains by altering PRC2 subtype equilibrium. Chan NT, Huang J, Ma G, Zeng H, Donahue K, Wang Y, Li L, Xu W. Nucleic Acids Res 50 1969-1992 (2022)
- Microtubule-associated protein MAP1LC3C regulates lysosomal exocytosis and induces zinc reprogramming in renal cancer cells. Verma R, Aggarwal P, Bischoff ME, Reigle J, Secic D, Wetzel C, VandenHeuvel K, Biesiada J, Ehmer B, Landero Figueroa JA, Plas DR, Medvedovic M, Meller J, Czyzyk-Krzeska MF. J Biol Chem 299 104663 (2023)